Study on the Treatment of Osteoporotic Vertebral Fractures Using Vertebral Body Stenting

NCT01847898 | Completed Phase 4

• 1 other identifier: STU-SPI-S-06-134-01
• Study Type: interventional
• Target: 100
• Locations: 2 countries
• Sites: 5

Brief Summary

This is a randomized, controlled study to document and evaluate the clinical performance of the Vertebral Body Stenting (VBS) System in osteoporotic fractures of the thoracic and lumbar spine. The randomized, controlled trial (RCT) will compare patients with VBS and Balloon Kyphoplasty.

Conditions

Vertebral Body Fractures

Keywords

Osteoporosis; Vertebral Body; Compression Fracture; Kyphoplasty

Outcome Measures

Primary Outcomes (3)

• Increase and maintenance of the vertebral body height

  The anterior edge, mid height and posterior edge of the index vertebral body are measured pre-operatively standing, after prone intraoperative positioning on the table (dynamic fracture mobility), intra-operatively following balloon dilation (height restoration), after balloon deflation and removal, after cement deposition, and finally postoperative standing. Anterior, middle and posterior height measurements will be made at each time-point during the study to measure maintenance of vertebral body height over time. The ratio between anterior and mid or posterior edge height (Beck-index) is calculated to avoid the problem of image calibration. In addition, the relative height fractions in comparison to the nearest healthy vertebral body (referent level) are calculated. Finally, local and regional sagittal angles and overall lumbar lordosis or thoracic kyphosis, respectively, are assessed for measurement of improvement of alignment.

  12 months

• Visual analog scale (VAS) for back pain

  Pain assessment by the patients using the VAS back pain from 0 to 10. In this scale 0 means "no pain" and 10 is the "worst pain imaginable". A pre- to postoperative difference of at least 2 observed during the course of the therapy is regarded as clinically relevant.

  12 months

• Adverse events

  * Any re-operations, revisions, and removals or supplemental fixation at the index level(s) is considered a study failure. * Any intra-operative system malfunction, misplacement of the balloon or stent, balloon or stent fracture, or failure of the balloon or stent to fully deploy is considered a study failure.

  12 months

Secondary Outcomes (8)

• Radiographic evaluations

  2 years

• Global assessment by the patient using the VAS

  2 years

• VAS leg pain

  2 years

• Analgesic usage

  2 years

• Neurological assessment of root tension signs, muscle strength, sensory deficit and reflexes

  2 years

Study Arms (2)

Vertebral Body Stenting (VBS)

EXPERIMENTAL

Procedure: Vertebral Body Stenting (VBS)

Balloon Kyphoplasty

EXPERIMENTAL

Procedure: Balloon Kyphoplasty

Interventions

Vertebral Body Stenting (VBS) PROCEDURE

Vertebral Augmentation with a Stent

Vertebral Body Stenting (VBS)

Balloon Kyphoplasty PROCEDURE

Vertebral Augmentation with a Balloon (device not specified)

Balloon Kyphoplasty

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 50
• to 3 contiguous target vertebral compression fractures (VCF) meeting the following criteria:
• Fracture due to diagnosed or presumed underlying primary or secondary osteoporosis (Patients with AO type A1.x fractures and A3.1 fractures may be included in the study).
• All target VCFs are between Th5 and L5
• All target VCFs to be treated show either:
• Height change: An acute (\< 6 month) change in VB height (\>15% height loss) with height loss at the anterior, middle or posterior portion of the VB consistent with a worsening of 1 or more grades by the Genant criteria, OR
• Positive MRI or bone scan: VB shows hyperintense signal on MRI-T2 or STIR sequence or target VB is positive on radionuclide bone scan
• Back pain correlating with the location of at least one VCF
• Treatment of all target VCFs is technically feasible by and clinically appropriate for BOTH vertebroplasty and balloon kyphoplasty
• No major surgery to the spine planned for at least 1 month following enrollment
• Pre-treatment back pain by numerical rating scale (NRS) score \>= 4 (0-10 scale)
• Subject is able to understand the risks and benefits of participating in the study and is willing to provide written informed consent
• Psychosocially, mentally and physically able to fully comply with the protocol requirements for the duration of the study including adhering to scheduled visits, treatment plan, completing forms and other study procedures

You may not qualify if:

• VB morphology or configuration is such that either balloon kyphoplasty OR vertebroplasty is not technically feasible for the targeted VCFs
• Fracture due to high-energy trauma
• Suspected OR proven cancer inside index vertebral body.
• Disabling back pain due to causes other than acute fracture (e.g., sacroiliac fracture, symptomatic degenerative disc disease, lumbar spinal stenosis)
• Any painful VCF with fracture age \> 6 months
• Patients with primary tumors of the bone (e.g., osteosarcoma) or solitary plasmacytoma at site of the index VCF. Patients with these tumors in anatomic sites other than the index VCF are eligible.
• Any objective evidence of neurologic compromise at baseline
• Previous balloon kyphoplasty or vertebroplasty for any VCF
• Spine stabilization beyond balloon kyphoplasty or vertebroplasty required for targeted VCFs
• Significant clinical comorbidity that may potentially interfere with long-term data collection or follow-up (e.g., dementia, severe comorbid illness)
• Patients requiring the use of high-dose steroid (\>= 100mg prednisone or 20 mg dexamethasone per day), IV pain medication, or nerve block to control chronic back pain unrelated to index VCF(s). Patients who receive high-dose steroids for treatment of their cancer (for at least 30 days) are eligible.
• Patients who may require allogeneic bone marrow transplantation during the course of the study
• Spinal cord compression or canal compromise requiring decompression
• Patients with osteoblastic tumors at the site of index VCF. Patients with osteoblastic tumors of vertebral levels not intended for kyphoplasty may be enrolled.
• MRI contraindication (e.g. cerebral aneurysm clips, pacemaker, implanted biostimulators, cochlear implants, penile prosthesis)

Sponsors & Collaborators

• Synthes GmbH: lead

Study Sites (5)

Universitätsklinik für Unfallchirurgie

Graz, Austria

Location

AKH

Vienna, Austria

Location

Universitätsklinikum Schleswig-Holstein

Kiel, Germany

Location

Universitätsklinikum

Münster, Germany

Location

Universitätsklinik und Poliklinik für Chirurgie

Rostock, Germany

Location

MeSH Terms

Conditions

Osteoporosis; Fractures, Compression

Interventions

Kyphoplasty

Condition Hierarchy (Ancestors)

Bone Diseases, Metabolic; Bone Diseases; Musculoskeletal Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases; Fractures, Bone; Wounds and Injuries

Intervention Hierarchy (Ancestors)

Vertebroplasty; Cementoplasty; Orthopedic Procedures; Therapeutics; Surgical Procedures, Operative

Study Officials

• Paul F. Heini, Prof. Dr. med.

  Klinik Sonnenhof, Bern, Switzerland

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 27, 2009
• First Posted: May 7, 2013
• Study Start: September 1, 2009
• Primary Completion: December 31, 2015
• Study Completion: December 31, 2015
• Last Updated: March 14, 2017

Record last verified: 2017-03

Locations

AU (2); DE (3)